What To Expect From Gilead In Q3 2025
Source: SeekingAlpha
2025-10-24 10:56:43 ET
Well, I am here again with my analysis of Gilead Sciences ( GILD ).
Since my last article, "Gilead Sciences: HIV Leadership Outshines Decline in COVID-19 Drug Sales," was published on 9/2, Gilead shares have risen 8.8%, outperforming the S&P 500 ( SPY ) [5.6% return], as well as the 'bellwether' for the biotech retail investors, the VanEck Biotech ETF ( BBH ) [6.7%]....
Read the full article on Seeking Alpha
For further details see:
What To Expect From Gilead In Q3 2025
Ipsen ADR
NASDAQ: IPSEY
IPSEY Trading
0.0% G/L:
$46.31 Last:
4,394 Volume:
$46.31 Open:
IPSEY Latest News
December 07, 2025 05:33:00 pm
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
December 05, 2025 05:00:00 am
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting
June 02, 2025 08:00:00 am
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
